Recombinant type e botulinum neurotoxin vaccine
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN266200500012C
- Awardee
-
Dynport Vaccine Company LLC UEI LXNEGTYDR755 Part of Computer Sciences Corporation
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,026,999
Award facts
- Opportunity
-
- NIHNIAIDDMIDPR200402 Solicitation number
- Contract value 100% obligated
- $3,026,999.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- NIAID DEA OA Acquisitions National Institutes of Health, Department of Health and Human Services
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $26,999 | |
| Original award | $3,000,000 |
About this award
This is a $3,026,999.00 firm fixed price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for the development of a recombinant Type E botulinum neurotoxin vaccine. The contract has a completion date of September 29, 2006 and does not use a set-aside designation.
Dynport Vaccine Company LLC is a limited liability company that provides research, development, manufacturing, and testing services for biopharmaceutical products targeting infectious diseases. The company has experience supporting the NIH, HHS, and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense through past federal contracts for preclinical development, clinical trials, diagnostics, and cGMP production of vaccine candidates.
This contract is likely part of NIH-NIAID's broader efforts to develop medical countermeasures against biological threats. Dynport's work under this award may involve process development, assay validation, pilot manufacturing, and stability testing to advance the recombinant botulinum vaccine towards clinical evaluation and potential licensure.
Quick answers
Who was awarded contract HHSN266200500012C?
HHSN266200500012C was awarded to Dynport Vaccine Company LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 2, 2005.
How much is contract HHSN266200500012C worth?
The government has obligated $3,026,999 on HHSN266200500012C.
Which agency awarded contract HHSN266200500012C?
National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded HHSN266200500012C, with funding from NIAID DEA OA Acquisitions (National Institutes of Health).
Was contract HHSN266200500012C competed?
The extent of competition for HHSN266200500012C was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award